Homology Medicines is a biopharmaceutical company with a focus on developing genetic medicines to alleviate the suffering of patients with rare genetic diseases. Their proprietary platform employs human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) for gene therapy or nuclease-free gene editing, enabling them to target a variety of disease-relevant tissues with a single injection. HMI-102 is their lead product candidate for the treatment of phenylketonuria and is currently undergoing a Phase 2 pheNIX clinical trial.